Formulary review of 2 new biologic agents: Tocilizumab for rheumatoid arthritis and ustekinumab for plaque psoriasis

Journal of Managed Care Pharmacy

Volumn 16, Issue 6, 2010, Pages 402-416

  Schafer, Jeremy A ^a   Kjesbo, Nicole K ^a   Gleason, Patrick P ^a,b  

^a Prime Therapeutics   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ALEFACEPT; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CHLOROQUINE; ETANERCEPT; GOLIMUMAB; HYDROXYCHLOROQUINE; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; SIMPONI; TOCILIZUMAB; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; USTEKINUMAB; MONOCLONAL ANTIBODY;

BODY SURFACE; CANCER RISK; CELL DIFFERENTIATION; CELLULITIS; CLINICAL TRIAL; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE COST; HUMAN; IMMUNE RESPONSE; INJECTION SITE REACTION; MONOTHERAPY; NEUTROPENIA; PHOTOTHERAPY; PNEUMONIA; PSORIASIS SEVERITY INDEX; PSORIASIS VULGARIS; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIDE EFFECT; T LYMPHOCYTE; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; ADULT; ECONOMICS; HEALTH INSURANCE; HOSPITALIZATION; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; PSORIASIS; PUBLICATION;

ADULT; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS, PHASE III AS TOPIC; FORMULARIES AS TOPIC; HUMANS; MANAGED CARE PROGRAMS; PSORIASIS; SEVERITY OF ILLNESS INDEX;

EID: 77957270719     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2010.16.6.402     Document Type: Review

References (55)

1. Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arth Rheum. 2008;58(1):15-25.
2. Pugner KM, Scott DI, Holmes JW, Hieke K. The costs of rheumatoid arthritis: an international long-term view. Semin Arthritis Rheum. 2000;29(5):305-20.
3. Joyce AT, Smith P, Khandker R, Melin JM, Singh A. Hidden cost of rheumatoid arthritis (RA): estimating cost of comorbid cardiovascular disease and depression among patients with RA. J Rheumatol. 2009;36(4):743-52.
4. Clarke A, Zowall H, Levinton C, et al. Direct and indirect medical costs incurred by Canadian patients with rheumatoid arthritis: a 12 year study. J Rheumatol. 1997;24(6):1051-60.
5. Sany J, Dropsy R, Daures JP. Cross-sectional epidemiological survey of rheumatoid arthritis patients seen in private practice in France: descriptive results (1629 cases). Rev Rhum Engl Ed. 1998;65(7-9):462-70.
6. Feldman S, Clark A. Psoriasis. Med Clin of N Amer. 1998;82(5):1135-44.
7. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9(2):136-39.
8. Simpson GL, Yelverton CB, Rittenberg S, Feldman SR. Do utilization management controls for phototherapy increase the prescription of biologics? J Dermatolog Treat. 2006;17(6):359-61.
9. Fowler JF, Duh MS, Rovba L, et al. The impact of psoriasis on health care costs and patient work loss. J Am Acad Dermatol. 2008;59(5):772-80.
10. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic diseasemodifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59(6):762-84. Available at: http://www3.interscience.wiley.com/cgi-bin/fulltext/119635887/ PDFSTART. Accessed June 8, 2010.
11. National Institute for Health and Clinical Excellence. Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis. NICE technology appraisal guidance 130. October 2007. Available at: http://www.nice.org.uk/nicemedia/live/11867/37914/37914.pdf. Accessed June 8, 2010.
12. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826-50.
13. Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ, Furstenberg CT. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum. 2007;56(1):13-20.
14. Rubbert-Roth A, Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther. 2009;11(Suppl 1):1. Available at: http://www.ncbi.nlm.nih.gov/pmc/ articles/PMC2669237/pdf/ar2666.pdf. Accessed June 8, 2010.
15. Agency for Healthcare Research and Quality. Comparative effectiveness of drug therapy for rheumatoid arthritis and psoriatic arthritis in adults. No.11. November 19, 2007. Available at: http://www.effectivehealthcare.ahrq.gov/ehc/ products/14/70/RheumArthritisExecSum.pdf. Accessed June 8, 2010.
16. Stelara (ustekinumab). Centocor Ortho Biotech Inc. December 30, 2009. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/ 125261s001lbl.pdf. Accessed June 8, 2010.
17. Actemra (tocilizumab) for intravenous infusion. Genentech. January 2010. Available at: http://www.gene.com/gene/products/information/actemra/pdf/pi.pdf. Accessed June 8, 2010.
18. U.S. Food and Drug Administration. Press release. FDA approves new drug to treat psoriasis. September 25, 2009. Available at: http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/2009/ucm183851.htm. Accessed June 8, 2010.
19. U.S. Food and Drug Administration. Press release. FDA approves new drug for rheumatoid arthritis. January 11, 2010. Available at: http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/ucm197108.htm. Accessed June 8, 2010.
20. Griffiths CE, Strober BE, van de Kerkhof P, et al., for the ACCEPT Study Group. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010;362(2):118-28.
21. Bartlett BL, Moody MN, Tyring SK. IL-12/IL-23 inhibitors: the advantage and disadvantages of this novel approach for the treatment of psoriasis. Skin Therapy Lett. 2008;13(8):1-4.
22. U.S. Food and Drug Administration. Center for Drug Evaluation and Research. Pharmacology review of ustekinumab. Application number 125261. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2009/125261s000- PharmR.pdf. Accessed June 8, 2010.
23. Lipsky PE. Interleukin-6 and rheumatic diseases. Arthritis Res Ther. 2006;8(Suppl 2):S4.
24. Nakahara H, Nishimoto N. Anti-interleukin-6 receptor antibody therapy in rheumatic diseases. Endocr Metab Immune Disord Drug Targets. 2006;6(4):373-81.
25. Leonardi CL, Kimball AB, Papp KA, et al., for the PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin- 12/23 monoclonal antibody, in patients with psoriasis: 76 week results from a randomised, double blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371(9625):1665-74.
26. Papp KA, Langley RG, Lebwohl M, et al., for the PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin- 12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371(9625):6175-84.
27. Langley RG, Feldman SR, Han C, et al. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate to severe psoriasis: results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol. 2010; May 10. Epub ahead of print.
28. Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicenter randomised placebo-controlled trial. Ann Rheum Dis. 2008;67(11):1516-23.
29. Smolen JS, Beaulieu A, Roth AR, et al., for the OPTION investigators. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371(9617):987-97.
30. Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006;54(9):2817-29.
31. Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug thereapy study. Arthritis Rheum. 2008;58(10):2968-80. Available at: http://www3.interscience.wiley.com/cgi-bin/fulltext/121425897/PDFSTART. Accessed June 8, 2010.
32. Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis. 2007;66(1):1162-67.
33. Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69(1):88-96.
34. U.S. Food and Drug Administration. Center for Drug Evaluation and Research. Medical review of ustekinumab. Application number 125261. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2009/125261s000-MedR.pdf. Accessed June 8, 2010.
35. Patel RV, Clark LN, Lebwohl M, Weinberg JM. Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol. 2009;60(6):1001-17.
36. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis. 2009;68(10):1580-84. Available at: http://ard.bmj.com/content/68/10/1580. full.pdf. Accessed June 8, 2010.
37. Remicade (infliximab). Centocor Ortho Biotech Inc. August 1998. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/1998/inflcen082498lb. pdf. Accessed March 30, 2010.
38. Remicade (infliximab). Centocor Ortho Biotech Inc. November 2009. Available at: http://www.remicade.com/remicade/assets/HCP-PPI.pdf. Accessed June 8, 2010.
39. Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, cross-over trial. Lancet. 2009;373(9664):633- 40.
40. Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371(9617):998-1006.
41. Clinicaltrials.gov. Search for ustekinumab. Available at: http://www.clinicaltrials.gov/ct2/results?term=ustekinumab. Accessed June 8, 2010.
42. Clinicaltrials.gov. Search for tocilizumab. Available at: http://www.clinicaltrials.gov/ct2/results?term=tocilizumab. Accessed June 8, 2010.
43. Prime Therapeutics internal data. Data on file. Costs are reported as total paid per member per month including all actual paid costs (ingredient cost, dispensing, and taxes) by the insurance plan and the member.
44. Finckh A, Bansback N, Marra CA, et al. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effective analysis. Ann Intern Med. 2009;151(9):612-21. Available at: http://www.annals.org/content/151/9/612.full.pdf+html. Accessed June 8, 2010.
45. Gleason PP, Starner CI, Gunderson BW, Schafer JA, Sarran HS. Association of prescription abandonment with cost share for high-cost specialty pharmacy medications. J Manag Care Pharm. 2009;15(8):648-58. Available at: http://www.amcp.org/data/jmcp/648-658.pdf.
46. Enbrel (etanercept). Wyeth. November 2009. Available at: http://www.0enbrel.com/documents/ENBREL-Prescribing-Information.pdf. Accessed June 8, 2010.
47. Humira (adalimumab). Abbott. November 2009. Available at: http://www.rxabbott.com/pdf/humira.pdf. Accessed June 8, 2010.
48. Cimzia (certolizumab). UCB Inc. November 2009. Available at: http://www.cimzia.com/pdf/Prescribing-Information.pdf. Accessed June 8, 2010.
49. Amevive (alefacept). Astellas Pharma US Inc. March 2009. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/125036s100lbl.pdf. Accessed June 8, 2010.
50. Kineret (anakinra). Amgen April 2004. Available at: http://www. accessdata.fda.gov/drugsatfda-docs/label/2004/103950s5039lbl.pdf. Accessed June 8, 2010.
51. Rituxan (rituximab). Genentech. February 2010. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/103705s5311lbl.pdf. Accessed June 8, 2010.
52. Simponi (golimumab). Centocor Ortho Biotech Inc. November 2009. Available at: http://www.simponi.com/Prescribing-Information/Prescribing-Information.pdf. Accessed June 8, 2010.
53. Orencia (abatacept). Bristol Myers Squibb. August 2009. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/125118s0086lbl.pdf. Accessed June 8, 2010.
54. Iwakura Y, Ishigame H. The IL-23/IL-17 axis in inflammation. J Clin Invest. 2006;116(5):1218-22. Available at: http://www.jci.org/articles/view/ 28508. Accessed June 8, 2010.
55. Wolters Kluwer Health. Medi-Span database. Accessed April 12, 2010.